成纖維細(xì)胞生長(zhǎng)因子15(FGF15)單克隆抗體
Monoclonal Antibody to Fibroblast Growth Factor 15 (FGF15)
- 編號(hào)UMAL154Ra23
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱(chēng)，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))C3
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPL154Ra01-成纖維細(xì)胞生長(zhǎng)因子15(FGF15)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 373 ¥ 869 ¥ 1242 ¥ 3105 ¥ 12420
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Rat Kidney Tissue; Primary Ab: 30μg/ml Mouse Anti-Rat FGF15 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)FGF15的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別FGF15。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Endocrinology. | Naringenin Prevents Obesity, Hepatic Steatosis, and Glucose Intolerance in Male Mice Independent of Fibroblast Growth Factor 21 [PubMed: 25774553] |
| Inflammatory Bowel Diseases | Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation [pubmed:27580383] |
| J Lipid Res. | Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. [pubmed:28130274] |
| BMC Endocrine Disorders | The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance [10.1186/s12902-017-0211-5] |
| Journal?of?Physiology?and?Biochemistry | The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice [Pubmed:29468415] |
| Developmental?Cell | FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis [Pubmed: 30745141] |
| Endocrinology | Interactions between the gravitostat and the fibroblast growth factor system for the regulation of body weight [] |
| Food & Function | Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis [Pubmed: 31626262] |
| Journal of Translational Medicine | Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation [Pubmed: 33036625] |
| Chin Med | Si-Wu-Tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis [34736501] |
| Int J Biol Sci | Dynamics of the gut-liver axis in rats with varying fibrosis severity [Pubmed:35637968] |
